Elafibranor is a dual PPARalpha/delta agonist (EC50 PPARalpha = 10-20 nM, PPARdelta = 100-150 nM).1 It was able to decrease plasma triglycerides levels1, increase HDL cholesterol levels in human studies1, and improve hepatic and peripheral insulin sensitivity2. Elafibranors antidiabetic effects in db/db were without the adverse cardiac effects seen in PPARgamma agonism.3 Elafibranor has also been shown to have therapeutic promise in the treatment of nonalcoholic steatohepatitis (NASH).4-6
* VAT and and shipping costs not included. Errors and price changes excepted
